Reading up on the Pharmaset buyout in this article I came accross this statement;

>>

Pharmasset’s PSI-7977 has been tested mostly for genotypes 2 and 3, which generally require only 24 weeks of treatment with the older drugs. In one small test, 10 of 10 patients treated with the drug and ribavirin were considered cured after only 12 weeks of treatment, a result that astounded researchers. It is less clear how well PSI-7977 will do against the tougher and more common genotype 1.<<

http://www.google.com/url?sa=t&rct=j&...X1kxCNpquw

I see many here would be glad with $50. buyout, however why would we not be worth VRUS type buy-out $ if the phase 2 trials go as planned? Just asking.

-bunny-